Arpeggio Bio
InactiveArpeggio Bio develops drugs targeting transcription factors using AI…
What it does
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
Next to it in Healthcare and bio · AI-assisted drug discovery for transcription factors
- Intrinsic Medicine (fka Lupa Bio)SOSV SOSV IndieBio 09
Developing the next generation of essential, disease-modifying medicines
- Known MedicineY Combinator S20
Combining 3D cell culture & AI to translate drugs to clinical success
- Civetbio500 Global
Provider of biotechnology service intended to accelerate drug discovery for live bio-therapeutics. The company's service includes a microbiota bank, a clinical intervention platform, and core big data technology that powers their bioinformatics pipeline, enabling researchers to characterize the Asian gut microbiome and understand the varying profiles across country regions.
- Valink TherapeuticsY Combinator W21
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
- Talus BioY Combinator S21
Discovering drugs that target the DNA regulome
- AlixiaY Combinator W22
Targeting the Tumor Ecosystem to address cancer drug resistance.
- Rosebud BiosciencesY Combinator W22
Growing micro-organs to find new drugs
- SyntheXSOSV SOSV IndieBio 03
Drugging the undruggable